Skip to main content
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. — Investor Relations & Filings

Ticker · MEDP ISIN · US58506Q1094 LEI · 549300H8TYEUVTW14A54 US Professional, scientific and technical activities
Open in API
Filings indexed 859 across all filing types
Latest filing 2018-08-13 Board/Management Inform…
Country US United States of America
Listing US MEDP

About Medpace Holdings, Inc.

https://investor.medpace.com/

Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services. The company serves the biotechnology, pharmaceutical, and medical device industries, with a mission to accelerate the development of safe and effective medical therapeutics. Medpace employs a disciplined operating approach that leverages regulatory and therapeutic expertise. Its services include clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core labs. The company has expertise across major therapeutic areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective diseases.

Recent filings

Filing Released Lang Actions
Board/Management Information 2018
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2018, reporting changes in the company's board of directors. It details the resignation of two directors and the election of two new directors, including their backgrounds and compensation arrangements. There is no financial data or discussion of financial results, nor is it an announcement of a report publication. The content fits the category of announcements related to changes in the company's board or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2018-08-13 English
AMENDMENT NO. 6 TO SCHEDULE 13D
Major Shareholding Notification
2018-08-10 English
FORM 4 SUBMISSION
Director's Dealing
2018-08-10 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2018, reporting the entry into a material definitive agreement related to an underwriting agreement for the sale of shares by a selling shareholder. It details the terms of the offering, the parties involved, and references the underwriting agreement as an exhibit. The document is 4457 characters long, which is relatively short and primarily serves as a current report to announce a specific event (the underwriting agreement and share sale). It does not contain financial statements or detailed financial performance data. This type of filing is best classified as a Capital/Financing Update (CAP) because it relates to financing activities and capital structure changes (sale of shares by a selling shareholder).
2018-08-09 English
FORM 4
Director's Dealing
2018-08-09 English
FORM 4
Director's Dealing
2018-08-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.